Scynexis Switches Focus To Hospital Indications For Ibrexafungerp
With sluggish sales so far for antifungal Brexafemme, approved for vulvovaginal candidiasis, Scynexis will look to out-license the product and cut staff.
You may also be interested in...
The US regulatory agency asked for more data and analyses for olorofim, which F2G hopes to provide from an ongoing Phase IIb study.
The pharma licensed global rights to Scynexis’s Brexafemme, a first-in-class triterpenoid antifungal approved for treat and prevent recurrence of vaginal yeast infections, for $90m up front.
Keeping Track: Rebyota, Rezlidhia Rev Up US FDA Approvals; New Sponsors Sought For Poziotinib, Brexafemme
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.